预约演示
更新于：2026-03-01
XXB-750
更新于：2026-03-01
概要
基本信息
药物类型 生物药 |
别名 XXB 750、XXB-750、XXB750 |
靶点 |
作用方式 激动剂 |
作用机制 NPRA激动剂(利钠肽受体1激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
关联
4
项与 XXB-750 相关的临床试验NCT06142383
A Multi-center, Randomized, Placebo- and Active-controlled, Parallel-group, 24-week Proof of Concept and Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Heart Failure
NCT05562934
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
NCT05328752
A Randomized, Participant- and Investigator-blinded, Sponsor Open-label, Placebo-controlled, Single and Multiple Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
100 项与 XXB-750 相关的临床结果
登录后查看更多信息
100 项与 XXB-750 相关的转化医学
登录后查看更多信息
100 项与 XXB-750 相关的专利（医药）
登录后查看更多信息
2
项与 XXB-750 相关的文献（医药）2026-01-01JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension
Article
作者: Jiao, Rong ; Nührenberg, Thomas ; Azizi, Michel ; Rizkala, Adel R ; Ferdinand, Keith ; Cohen, Debbie L ; Lefkowitz, Martin ; White, William B ; Maboudian, Mojdeh ; Williams, Bryan
BACKGROUND:
XXB750 is a potent and long-acting human monoclonal antibody agonist of the natriuretic peptide receptor-1 (NPR-1), the receptor for atrial natriuretic peptide and B-type natriuretic peptide. Activation of NPR-1 may lower blood pressure (BP) in patients with resistant hypertension through increases in the second messenger cyclic guanosine monophosphate.
OBJECTIVES:
The aim of this study was to determine the effect of NPR-1 agonism on 24-hour BP.
METHODS:
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial evaluated 4 once-monthly subcutaneous doses of XXB750 (30 mg, 60 mg, 120 mg, and 240 mg) administered at baseline, week 4, and week 8 in patients with resistant hypertension. Resistant hypertension was defined as 24-hour systolic BP (SBP) ≥135 mm Hg despite treatment with 3 or 4 guideline-directed antihypertensive agents. The primary endpoint was the dose-response relationship of XXB750 vs placebo in reducing the mean 24-hour SBP from baseline to week 12.
RESULTS:
The study population (N = 189) had a mean age of 61 years, was 69% male, 61% White, 20% Asian, and 14% Black/African American, and had a baseline mean 24-hour ambulatory BP of 148/81 ± 11/10 mm Hg. Plasma concentrations of XXB750 dose-dependently increased in the XXB750 groups, and XXB750 dose-dependently increased plasma and urine cyclic guanosine monophosphate concentrations by week 12. However, paradoxically, there was no significant dose-dependent change from baseline in mean 24-hour SBP at week 12. In fact, none of the doses of XXB750 had a greater BP-lowering effect than placebo. Changes in ambulatory BP were not affected by the development of anti-drug antibodies. Although there were no changes from baseline in urinary sodium excretion, there were small increases in plasma renin levels in the XXB750 groups. Adverse events with XXB750 were numerically higher than with placebo. Adherence to background antihypertensive medications, assessed by drug assays in 88 patients with available plasma samples, was consistent across all treatment groups at both baseline and week 12.
CONCLUSIONS:
XXB750, an NPR-1 agonist, had a neutral effect on 24-hour ambulatory SBP in patients with resistant hypertension, despite showing a robust dose-response relationship for engagement of the target of pharmacologic action as indicated by increases in cyclic guanosine monophosphate levels. (An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients; NCT05562934).
2025-05-27CIRCULATION
Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study
Letter
作者: Yates, Denise P. ; Kulmatycki, Kenneth ; Nguyen, David ; O’Donnell, Christopher J. ; Healy, Emma ; Wu, Xueping ; Hinder, Markus ; Russo, Cesare ; Yan, Jing-He ; Zhang, Tong ; Diener, John L. ; Kinhikar, Arvind G. ; Markiewicz, Maggie ; He, YanLing ; Serra-Roma, Andre
100 项与 XXB-750 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床2期 | 美国 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 美国 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 美国 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 美国 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 中国 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 日本 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 日本 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 日本 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 日本 | 2023-12-12 | |
| 心脏衰竭 | 临床2期 | 保加利亚 | 2023-12-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 136 | XXB750 Placebo (XXB750 Placebo (Arm 1)) | 鹹夢遞製蓋窪構艱範廠(網襯艱醖選窪襯積製襯) = 齋構顧鹽衊鹹製鏇膚網 構淵築築製繭網選艱製 (遞夢憲鑰膚獵艱願遞膚, 構憲壓蓋遞網願願製醖 ~ 製淵醖壓築構積選廠夢) 更多 | - | 2025-12-24 | ||
(XXB750 60 mg (Arm 2)) | 鹹夢遞製蓋窪構艱範廠(網襯艱醖選窪襯積製襯) = 醖鹽顧範鑰艱鑰顧範構 構淵築築製繭網選艱製 (遞夢憲鑰膚獵艱願遞膚, 襯夢鑰糧窪範憲鬱鬱壓 ~ 蓋壓醖衊繭憲餘願淵蓋) 更多 | ||||||
临床2期 | 189 | Placebo (Placebo) | 窪衊夢鹽醖遞觸遞蓋窪(構願構夢壓獵餘糧觸願) = 艱齋糧構鹹簾齋獵範蓋 廠膚壓鹽鏇願憲築襯鬱 (觸廠窪積網築選鬱簾選, 範齋範鹹廠顧壓鏇醖壓 ~ 網觸願膚觸鏇觸積鹹範) 更多 | - | 2025-10-24 | ||
(XXB750 30 mg) | 窪衊夢鹽醖遞觸遞蓋窪(構願構夢壓獵餘糧觸願) = 遞鹽網壓願餘鏇糧鹹繭 廠膚壓鹽鏇願憲築襯鬱 (觸廠窪積網築選鬱簾選, 廠窪夢鑰製製繭窪願齋 ~ 觸獵簾鹽膚遞網淵獵繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用